DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction

Key Takeaway: DiaMedica Therapeutics has announced the dosing of the first patients in a Phase 2 trial for DM199, aimed at treating fetal growth restriction. This marks a significant step in their clinical development process. Further details regarding the trial's objectives and expected outcomes were not provided.